2021 New Mexico Statutes
Article 1 - General Provisions
Section 26-1-3 - Prohibited acts.

The following acts are prohibited:
A. the sale of any drug or device that is adulterated, misbranded or a counterfeit drug which is not a controlled substance;
B. the adulteration or misbranding of any drug or device;
C. the receipt or delivery in commerce of any drug or device that is adulterated, misbranded or a counterfeit drug which is not a controlled substance;
D. the dissemination of any false advertisement;
E. the giving of a false guaranty or undertaking, except by a person who relied on a guaranty or undertaking as attested by label or labeling from whom he received in good faith the drug or device for sale;
F. any act with respect to a drug or device when the act is done while the drug or device is held for sale and results in the drug or device being misbranded or adulterated;
G. the creation, sale, disposition, possession or concealment of any punch, die, plate, stone or other thing designed to print, imprint or reproduce the trademark, trade name or other identifying mark, imprint, device of another or any likeness of any of the foregoing upon any drug or container or labeling so as to render the drug a counterfeit drug;
H. concealment, disposition or possession with intent to sell or preparation with intent to defraud of a counterfeit drug;
I. in the case of a dangerous drug distributed or offered for sale in this state, the failure of the manufacturer or repackager to transmit, to any practitioner licensed to administer the drug who makes a written request for information, true and correct copies of all printed matter which is required to be included in any package in which that drug is distributed or sold or such other printed matter as is approved under the federal act. Nothing in this subsection shall be construed to exempt any person from any labeling requirement imposed under other provisions of the New Mexico Drug, Device and Cosmetic Act [26-1-1 NMSA 1978] and the Controlled Substances Act [Chapter 30, Article 31 NMSA 1978]; and
J. except as provided in Sections 26-3-1 through 26-3-3 NMSA 1978, dispensing or causing to be dispensed a different drug or brand of drug in place of the drug or brand of drug ordered or prescribed without the express permission in each case of the person ordering or prescribing.
History: 1953 Comp., § 54-6-28, enacted by Laws 1967, ch. 23, § 3; 1972, ch. 84, § 44; 1976, ch. 60, § 1; 1987, ch. 270, § 3.
Cross references. — For definitions, see 26-1-2 NMSA 1978.
For adulteration of drug or device, see 26-1-10 NMSA 1978.
For adulteration of cosmetics, see 26-1-25 NMSA 1978.
For penalties, see 26-1-26 NMSA 1978.
For the definition of "federal act", see 26-1-2W NMSA 1978.
The 1987 amendment, effective June 19, 1987, deleted "or cosmetic" following "drug or device" throughout the section; in the last sentence in Subsection I inserted "Device"; in Subsection J substituted "Sections 26-3-1 through 26-3-3 NMSA 1978" for "Sections 54-6-28.1 through 54-6-28.3 NMSA 1953"; and made minor stylistic changes throughout the section.

Structure 2021 New Mexico Statutes

2021 New Mexico Statutes

Chapter 26 - Drugs and Cosmetics

Article 1 - General Provisions

Section 26-1-1 - Short title.

Section 26-1-2 - Definitions.

Section 26-1-3 - Prohibited acts.

Section 26-1-3.1 - Repealed.

Section 26-1-3.2 - Prescription drug donation.

Section 26-1-4 - Power to enjoin violations.

Section 26-1-5 - Penalty; exemptions.

Section 26-1-6 - Detection of drugs, devices or cosmetic believed adulterated, misbranded or counterfeit; condemnation; destruction or correction of defect; forfeiture and sale.

Section 26-1-7 - Attorney general or district attorney to institute prosecutions.

Section 26-1-8 - Minor violations of act; warnings authorized.

Section 26-1-9 - Addition of poisonous or deleterious substances; color additives.

Section 26-1-10 - Drug or device adulteration.

Section 26-1-11 - Drug or device; misbranding.

Section 26-1-12 - False advertising.

Section 26-1-13 - Packaging and labeling requirements; proprietary preparations.

Section 26-1-14 - New drugs and devices; prerequisites to sale, delivery or giving away; exceptions.

Section 26-1-15 - Dangerous drugs; veterinary use; limitations.

Section 26-1-16 - Dangerous drugs; conditions for sale; prescription refilling; limitations.

Section 26-1-16.1 - Opioids; requiring practitioners to obtain and review reports from the prescription monitoring program.

Section 26-1-17 - Testing laboratory.

Section 26-1-18 - Promulgating regulations; procedure.

Section 26-1-18.1 - Prescription drug prior authorization protocols.

Section 26-1-19 - Power to make inspections and secure samples.

Section 26-1-20 - Personnel.

Section 26-1-21 - Power of board to publish reports and disseminate information.

Section 26-1-22 - Unlawful means of obtaining dangerous drugs enumerated.

Section 26-1-23 - False statements; false pretenses; forgery of labels or prescriptions prohibited.

Section 26-1-24 - Cosmetics; misbranding.

Section 26-1-25 - Cosmetics; adulteration.

Section 26-1-26 - Penalties.